Racial and ethnic differences in pharmacotherapy to prevent coronary artery disease and thrombotic events
Awareness of racial/ethnic disparities represents a key challenge for healthcare systems that
attempt to provide effective healthcare and to reduce existing inequalities in the use of and …
attempt to provide effective healthcare and to reduce existing inequalities in the use of and …
Epidemiology of diabetes and atherosclerotic cardiovascular disease among Asian American adults: implications, management, and future directions: a scientific …
Asian American individuals make up the fastest growing racial and ethnic group in the
United States. Despite the substantial variability that exists in type 2 diabetes and …
United States. Despite the substantial variability that exists in type 2 diabetes and …
Efficacy and safety of tafolecimab in Chinese patients with heterozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled phase 3 trial …
M Chai, Y He, W Zhao, X Han, G Zhao, X Ma, P Qiao… - BMC medicine, 2023 - Springer
Abstract Background Heterozygous familial hypercholesterolemia (HeFH) is largely
underdiagnosed and undertreated in China where few patients achieved recommended …
underdiagnosed and undertreated in China where few patients achieved recommended …
Efficacy and Safety of Evolocumab in Chinese Patients with Primary Hypercholesterolemia and Mixed Dyslipidemia: 12-Week Primary Results of the HUA TUO 华佗 …
H Tan, W Li, Z Huang, Y Han, X Huang, D Li… - Cardiology and …, 2023 - Springer
Introduction Evolocumab, a fully human proprotein convertase/subtilisin kexin type 9
inhibitor antibody, significantly lowers low-density lipoprotein cholesterol (LDL-C) in patients …
inhibitor antibody, significantly lowers low-density lipoprotein cholesterol (LDL-C) in patients …
Ocular disorders associated with PCSK9 inhibitors: A pharmacovigilance disproportionality analysis
X Zhao, J Wu, S Zhu - British Journal of Clinical Pharmacology, 2023 - Wiley Online Library
Aims To identify and characterize ocular adverse events (oAEs) that are significantly
associated with proprotein convertase subtilisin‐like/kexin type 9 (PCSK9) inhibitors using …
associated with proprotein convertase subtilisin‐like/kexin type 9 (PCSK9) inhibitors using …
PCSK9 inhibitors reduce PCSK9 and early Atherogenic biomarkers in stimulated human coronary artery endothelial cells
Despite reports on the efficacy of proprotein convertase subtilisin-Kexin type 9 (PCSK9)
inhibitors as a potent lipid-lowering agent in various large-scale clinical trials, the anti …
inhibitors as a potent lipid-lowering agent in various large-scale clinical trials, the anti …
[HTML][HTML] Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients Following Acute Coronary Syndromes: From Lipid Lowering and Plaque Stabilization to …
K Dimitriadis, N Pyrpyris, P Iliakis, E Beneki… - Journal of Clinical …, 2024 - mdpi.com
Lipid lowering, with the use of statins after an acute coronary syndrome (ACS), is a
cornerstone, well-established strategy for the secondary prevention of ischemic events in …
cornerstone, well-established strategy for the secondary prevention of ischemic events in …
Patient adherence to fully reimbursed proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) treatment
A Stummer, R Ristl, B Kogler, M Muskovich… - Wiener klinische …, 2023 - Springer
Aims Proprotein convertase subtilisin/kexin-type 9 inhibitor (PCSK9i) treatment reduces
cardiovascular events when taken over a long time for secondary prevention. Data on …
cardiovascular events when taken over a long time for secondary prevention. Data on …
Methodology and results of cost-effectiveness of LDL-C lowering with evolocumab in patients with acute myocardial infarction in China
Y Wan, J Liu, X Zhan, Y Zhang, R You - Cost Effectiveness and Resource …, 2023 - Springer
Abstract Background According to the Chinese guidelines for lipid management (2023),
evolocumab in combination with statins was recommended as secondary prevention of …
evolocumab in combination with statins was recommended as secondary prevention of …
Cost-effectiveness of Evolocumab in Adult patients with atherosclerotic Cardiovascular Disease from Chinese Healthcare Perspective
W Xie, Y Song, X Qin, P Jin - Advances in Therapy, 2023 - Springer
Introduction To assess the cost-effectiveness of evolocumab with statins versus placebo
combined with statins in the treatment of adult patients with atherosclerotic cardiovascular …
combined with statins in the treatment of adult patients with atherosclerotic cardiovascular …